Milacron Holdings (MCRN) At $18.65 Forms Top; Delmar Pharmaceuticals (DMPI) Shorts Decreased By 13.32%

June 15, 2017 - By Peter Erickson

Delmar Pharmaceuticals Incorporated (NASDAQ:DMPI) had a decrease of 13.32% in short interest. DMPI’s SI was 104,800 shares in June as released by FINRA. Its down 13.32% from 120,900 shares previously. With 40,800 avg volume, 3 days are for Delmar Pharmaceuticals Incorporated (NASDAQ:DMPI)’s short sellers to cover DMPI’s short positions. About 14,287 shares traded. DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has declined 57.32% since June 15, 2016 and is downtrending. It has underperformed by 74.02% the S&P500.

Milacron Holdings Corp (MCRN) formed multiple top with $19.77 target or 6.00% above today’s $18.65 share price. Milacron Holdings Corp (MCRN) has $1.25B valuation. About 24,110 shares traded. Milacron Holdings Corp (NYSE:MCRN) has risen 16.99% since June 15, 2016 and is uptrending. It has outperformed by 0.29% the S&P500.

Analysts await Milacron Holdings Corp (NYSE:MCRN) to report earnings on July, 27. They expect $0.41 EPS, 0.00% or $0.00 from last year’s $0.41 per share. MCRN’s profit will be $27.48M for 11.37 P/E if the $0.41 EPS becomes a reality. After $0.32 actual EPS reported by Milacron Holdings Corp for the previous quarter, Wall Street now forecasts 28.13% EPS growth.

Among 7 analysts covering Milacron Holdings Corp (NYSE:MCRN), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Milacron Holdings Corp had 11 analyst reports since August 4, 2015 according to SRatingsIntel. JP Morgan initiated the shares of MCRN in report on Tuesday, August 4 with “Neutral” rating. The firm has “Outperform” rating given on Tuesday, August 4 by William Blair. Robert W. Baird initiated Milacron Holdings Corp (NYSE:MCRN) on Tuesday, August 4 with “Outperform” rating. As per Tuesday, August 4, the company rating was initiated by Bank of America. The stock has “Overweight” rating by Barclays Capital on Tuesday, August 4. On Tuesday, August 4 the stock rating was initiated by Credit Suisse with “Neutral”. The stock of Milacron Holdings Corp (NYSE:MCRN) earned “Overweight” rating by Barclays Capital on Monday, October 5. Goldman Sachs initiated the shares of MCRN in report on Tuesday, August 4 with “Neutral” rating. The firm earned “Overweight” rating on Tuesday, August 4 by KeyBanc Capital Markets.

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The company has market cap of $22.90 million. The Firm focuses on the treatment of cancer. It currently has negative earnings. The Firm is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme , a form of brain cancer.